Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20
Cohort 1 patients exhibited a significant immune response consistent with the mechanism of action Safety Review Committee approved continuation to the next cohort of patients NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: …